Trevor

Trevor Baglin, MedScD, PhD

Co-Founder & Chief Medical Officer

ApcinteX

Trevor Baglin, MedScD, PhD, is the Co-Founder and Chief Medical Officer at ApcinteX and the Chief Medical Officer at Z Factor. He is also a Venture Partner in the Medicxi investment team where he co-founded XO1 (acquired by Janssen Pharmaceuticals).

Prior to joining Medicxi, Trevor was a clinician at Cambridge University Hospitals where he was also Director of Investigative Sciences. His main research interests were in personalized risk profiling, developed from studying the gene-environment interaction leading to thrombosis, and the molecular basis of blood coagulation, which led to his interest in drug discovery and development. He has published more than 300 clinical and scientific papers and led the production of many international and UK clinical guidelines.

Trevor served as President of the British Society for Haematology and President of the British Society for Haemostasis and Thrombosis and was a Founder of the European Congress on Thrombosis and Haemostasis.

He qualified in Medicine from The University of Manchester and was awarded his PhD from the University of Birmingham and Doctor of Medical Science from Cambridge University. He is a Fellow of the Royal College of Physicians and a Fellow of the Royal College of Pathologists.

Read more here about ApcinteX

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser

×